Thank you for standing by, and welcome to the Apellis Pharmaceuticals fourth quarter and full year 2024 earnings conference call. (Operator Instructions) After the speaker's presentation, there will ...

Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NTLA) to Sell from Neutral with a price target of $9, down from $12, ...

Goldman Sachs analyst Salveen Richter initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target a Summit’s lead ...

In the assessment of 12-month price targets, analysts unveil insights for Apellis Pharmaceuticals, presenting an average ...

John Leonard; President, Chief Executive Officer, Director; Intellia Therapeutics Inc David Lebwohl; Executive Vice President, Chief Medical Officer; Intellia Therapeutics Inc Edward Dulac; Executive ...

Operator Good afternoon, and welcome to the Sarepta Therapeutics fourth quarter and full year 2024 financial results ...

Apellis Pharmaceuticals (NASDAQ:APLS) reported its fourth-quarter 2024 earnings, revealing a significant revenue increase and a narrower-than-expected loss per share. The company posted an actual ...

Ladies and gentlemen, good morning and welcome to the Taysha Gene Therapies Full Year 2024 Conference Call. At this time all participants are in listen-only mode. A brief question-and-answer session ...

Thank you, Salveen. So, I think, first of all, really important to bear in mind, injections continue to grow, right? And that is a reflection of the unmet need in this disease. Remember ...

Taysha Gene Therapies Inc. (TSHA) reported its Q4 2024 earnings on February 26, 2025, revealing a narrower-than-expected loss. The company posted an earnings per share (EPS) of -$0.07, beating the ...

Across the recent three months, 6 analysts have shared their insights on Intellia Therapeutics (NASDAQ:NTLA), expressing a variety of opinions spanning from bullish to bearish. The table below ...